Active phone prompts spur Rx adherence rates among consumers, CVS reveals
WOONSOCKET, R.I. Consumers are much more likely to adhere to their prescription medication therapy if given “a clear and active choice” in recorded telephone prompts from their pharmacy, new research into patient compliance from CVS Caremark demonstrated.
The company announced Thursday the results of a long-term research project into patient behavior, conducted by its Behavior Change Research Partnership. Those findings, presented at a Pittsburgh Business Group on Health symposium, underline a clear connection between encouraging patients to get their maintenance medications refilled and improved adherence rates.
“Ongoing research into how behavioral economics impacts healthcare choices found that when consumers are presented with a clear and active choice in a voice-recorded message to select automatic prescription refills, rather than a passive default notification, they are twice as likely to choose the automatic option,” CVS said.
CVS established the BCRP in March to study how behavioral economics impacts consumer healthcare decisions. The research group also was created “to help the company better understand why some patients stop taking maintenance medications for chronic illnesses,” the company noted.
The research results were presented by Troyen Brennan, CVS Caremark EVP and chief medical officer. “The preliminary findings show that by making choices clear and by streamlining messages, consumers sign up at twice the rate of those who are passively presented opt-in choices,” Brennan told Pittsburgh business leaders Thursday. “This research will help us develop programs to encourage people to stay on their medications, because nonadherence is costing the healthcare system billions of dollars every year.”
The BCRP research, titled “Active Choice,” is testing options in four communication channels, CVS said. Those channels include interactive Web sign-ins, in-bound customer calls to care centers, automated outbound telephone calls and direct mail.
“The testing shows some options offered to consumers today are overlooked because the choices are not readily transparent,” the company said. “Past industry studies show one-quarter of people receiving prescriptions never fill their first prescriptions, and patients with chronic diseases, such as diabetes and coronary artery disease, adhere to their ongoing medication regimen about half of the time.”
The BCRP panel is led by Punam Anand Keller of the Tuck School of Business at Dartmouth College, George Loewenstein of Carnegie Mellon University and Kevin Volpp of University of Pennsylvania’s Medical School and The Wharton School of Business. The presentation in Pittsburgh continued discussion of BCRP research that was first presented at a Centers for Disease Control and Prevention symposium in Atlanta last month.
Greenstone, Eisai to launch authorized generic of Aricept
PEAPACK, N.J. The generics division of Pfizer will sell an authorized generic version of a drug used to treat dementia.
Greenstone said Wednesday that it had agreed with Eisai to launch donepezil hydrochloride tablets, an authorized generic of Aricept. The drug is used to treat dementia related to Alzheimer’s disease. Eisai makes the drug under a partnership with Pfizer.
“We are excited about the opportunity to work with Eisai to introduce this important authorized generic to patients,” said James Cannon, Greenstone’s VP business alliances. “First and foremost, our goal is to provide donepezil hydrochloride tablets to the broad customer base, and we also strive to remain competitive with other potential generic versions of the product.”
Unlike generic drugs, which are marketed in competition with their branded counterparts and must undergo an abbreviated regulatory approval process through the Food and Drug Administration, authorized generics are essentially branded drugs marketed under their generic names with the authorization of the original drug’s manufacturer and often through third-party companies.
Lack of sleep may increase IFG risk, study finds
NEW YORK Lack of beauty sleep may up one’s risk of developing a condition that leads to diabetes and heart disease, a new study found.
Researchers from Warwick Medical School and the State University of New York at Buffalo examined six years of data from 1,455 participants in the Western New York Health Study, all of whom were between the ages of 35 and 79 years, and found that people who sleep less than six hours a night may be three times more likely to develop incident-impaired fasting glycaemia. IFG causes the body to be unable to regulate glucose as efficiently as it should.
Lead author at Warwick Medical School Dr. Saverio Stranges said: "We found that short sleep, less than six hours, was associated with a significant, threefold increased likelihood of developing IFG, compared [with] people who got an average of six to eight hours sleep a night. Previous studies have shown that short sleep duration results in a 28% increase in mean levels of the appetite stimulating hormone ghrelin so it can affect feeding behaviors. Other studies have also shown that a lack of sleep can decrease glucose tolerance and increases the production of cortisol, a hormone produced in response to stress."
Stranges added that, "more research is needed, but our study does suggest a very strong correlation between lack of sleep and Type 2 diabetes and heart disease."
The study was published in the journal Annals of Epidemiology.